Article info
PDFRheumatoid arthritis
Original article
Real-world predictors of 12–month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study
- Correspondence to Prof Dr Rieke Alten, Department of Internal Medicine, Rheumatology, Clinical Immunology, and Osteology Schlosspark-Klinik University Medicine Berlin Germany ; rieke.alten{at}schlosspark-klinik.de
Citation
Real-world predictors of 12–month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study
Publication history
- Received July 12, 2017
- Revision received November 23, 2017
- Accepted December 1, 2017
- First published December 29, 2017.
Online issue publication
July 06, 2018
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/